Clinical Trial Detail

NCT ID NCT03899467
Title the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Suzhou Kintor Pharmaceutical Inc,
Indications

prostate cancer

Therapies

Proxalutamide

Age Groups: senior adult

No variant requirements are available.